"$ALLK Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma https://t.co/jU3qPh35nq"

lirentelimab (AK002) - Allakos

Nov 30, 2021